162 related articles for article (PubMed ID: 31292998)
21. A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657.
Sohal J; Phan VT; Chan PV; Davis EM; Patel B; Kelly LM; Abrams TJ; O'Farrell AM; Gilliland DG; Le Beau MM; Kogan SC
Blood; 2003 Apr; 101(8):3188-97. PubMed ID: 12515727
[TBL] [Abstract][Full Text] [Related]
22. Acute promyelocytic leukemia with isochromosome 17q and cryptic PML-RARA successfully treated with all-trans retinoic acid and arsenic trioxide.
Shepshelovich D; Oniashvili N; Parnes D; Klein A; Muchtar E; Yeshaya J; Aviram A; Rabizadeh E; Raanani P
Cancer Genet; 2015 Nov; 208(11):575-9. PubMed ID: 26471811
[TBL] [Abstract][Full Text] [Related]
23. Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia.
Lou Y; Qian W; Meng H; Mai W; Tong H; Tong Y; Huang J; Jin J
Hematol Oncol; 2014 Mar; 32(1):40-6. PubMed ID: 23963734
[TBL] [Abstract][Full Text] [Related]
24. Identification and monitoring of atypical PML/RARA fusion transcripts in acute promyelocytic leukemia.
Iaccarino L; Divona M; Ottone T; Cicconi L; Lavorgna S; Ciardi C; Alfonso V; Travaglini S; Facchini L; Cimino G; Di Bona E; Voso MT; Lo-Coco F
Genes Chromosomes Cancer; 2019 Jan; 58(1):60-65. PubMed ID: 30421475
[TBL] [Abstract][Full Text] [Related]
25. Clinico-biological features and prognostic significance of PML/RARalpha isoforms in adult patients with acute promyelocytic leukemia treated with all trans retinoic acid (ATRA) and chemotherapy.
Gupta V; Yib QL; Brandwein J; Chun K; Lipton JH; Messner H; Schuh AC; Wells RA; Minden MD; Kamel-Reidc S
Leuk Lymphoma; 2004 Mar; 45(3):469-80. PubMed ID: 15160908
[TBL] [Abstract][Full Text] [Related]
26. PML/RAR alpha transcripts monitored by polymerase chain reaction in acute promyelocytic leukemia during complete remission, relapse and after bone marrow transplantation.
Perego RA; Marenco P; Bianchi C; Cairoli R; Urbano M; Nosari AM; Muti G; Morra E; Del Monte U
Leukemia; 1996 Feb; 10(2):207-12. PubMed ID: 8637228
[TBL] [Abstract][Full Text] [Related]
27. Using quantification of the PML-RARalpha transcript to stratify the risk of relapse in patients with acute promyelocytic leukemia.
Santamaría C; Chillón MC; Fernández C; Martín-Jiménez P; Balanzategui A; García Sanz R; San Miguel JF; González MG
Haematologica; 2007 Mar; 92(3):315-22. PubMed ID: 17339180
[TBL] [Abstract][Full Text] [Related]
28. Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study.
Lucena-Araujo AR; Kim HT; Jacomo RH; Melo RA; Bittencourt R; Pasquini R; Pagnano K; Fagundes EM; Chauffaille Mde L; Chiattone CS; Lima AS; Ruiz-Argüelles G; Undurraga MS; Martinez L; Kwaan HC; Gallagher R; Niemeyer CM; Schrier SL; Tallman MS; Grimwade D; Ganser A; Berliner N; Ribeiro RC; Lo-Coco F; Löwenberg B; Sanz MA; Rego EM
Ann Hematol; 2014 Dec; 93(12):2001-10. PubMed ID: 24981688
[TBL] [Abstract][Full Text] [Related]
29. Comparison of induction therapy in non-high risk acute promyelocytic leukemia with arsenic trioxide or in combination with ATRA.
Ghavamzadeh A; Jalili M; Rostami S; Yaghmaie M; Aliabadi LS; Mousavi SA; Vaezi M; Fumani HK; Jahani M; Alimoghaddam K
Leuk Res; 2018 Mar; 66():85-88. PubMed ID: 29407588
[TBL] [Abstract][Full Text] [Related]
30. The PML-RAR alpha transcript in long-term follow-up of acute promyelocytic leukemia patients.
Gameiro P; Vieira S; Carrara P; Silva AL; Diamond J; Botelho de Sousa A; Mehta AB; Prentice HG; Guimarães JE; Hoffbrand AV; Foroni L; Parreira A
Haematologica; 2001 Jun; 86(6):577-85. PubMed ID: 11418366
[TBL] [Abstract][Full Text] [Related]
31. Epigallocatechin-3-gallate promotes all-trans retinoic acid-induced maturation of acute promyelocytic leukemia cells via PTEN.
Yao S; Zhong L; Chen M; Zhao Y; Li L; Liu L; Xu T; Xiao C; Gan L; Shan Z; Liu B
Int J Oncol; 2017 Sep; 51(3):899-906. PubMed ID: 28766684
[TBL] [Abstract][Full Text] [Related]
32. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
Burnett AK; Russell NH; Hills RK; Bowen D; Kell J; Knapper S; Morgan YG; Lok J; Grech A; Jones G; Khwaja A; Friis L; McMullin MF; Hunter A; Clark RE; Grimwade D;
Lancet Oncol; 2015 Oct; 16(13):1295-305. PubMed ID: 26384238
[TBL] [Abstract][Full Text] [Related]
33. Molecular follow-up of patients with promyelocytic leukaemia treated with all-trans retinoic acid.
Ruiz-Argüelles GJ; Garcés-Eisele J; Ruiz-Argüelles A
Clin Lab Haematol; 1998 Jun; 20(3):173-6. PubMed ID: 9681233
[TBL] [Abstract][Full Text] [Related]
34. Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy.
Cicconi L; Breccia M; Franceschini L; Latagliata R; Molica M; Divona M; Diverio D; Rizzo M; Ottone T; Iaccarino L; Alfonso V; Foa R; Voso MT; Lo-Coco F
Ann Hematol; 2018 Oct; 97(10):1797-1802. PubMed ID: 29951912
[TBL] [Abstract][Full Text] [Related]
35. Influence of bcr-3 PML-RARα transcript on outcome in Acute Promyelocytic Leukemia patients of Kashmir treated with all-trans retinoic acid and/or arsenic tri-oxide.
Baba SM; Shah ZA; Pandith AA; Dil-Afroze ; Jan A; Mir KA; Aziz SA; Ahmad Z
Cancer Genet; 2019 Feb; 231-232():14-21. PubMed ID: 30803552
[TBL] [Abstract][Full Text] [Related]
36. The molecular biology of acute promyelocytic leukemia.
Slack JL; Gallagher RE
Cancer Treat Res; 1999; 99():75-124. PubMed ID: 9891864
[TBL] [Abstract][Full Text] [Related]
37. [Detection of the PML/RAR alpha rearrangement in acute promyelocytic leukemia using a reverse PCR method].
Barragán E; Bonanad S; López JA; Martín G; Martínez J; Sanz GF; Gomis F; Pérez ML; Senent ML; Larrea L; Bolufer P; Sanz MA
Sangre (Barc); 1996 Jun; 41(3):189-94. PubMed ID: 8755206
[TBL] [Abstract][Full Text] [Related]
38. Treatment of an acute promyelocytic leukemia relapse using arsenic trioxide and all-trans-retinoic in a 6-year-old child.
Rock N; Mattiello V; Judas C; Huezo-Diaz P; Bourquin JP; Gumy-Pause F; Ansari M
Pediatr Hematol Oncol; 2014 Mar; 31(2):143-8. PubMed ID: 24498972
[TBL] [Abstract][Full Text] [Related]
39. High WT1 expression is an early predictor for relapse in patients with acute promyelocytic leukemia in first remission with negative PML-RARa after anthracycline-based chemotherapy: a single-center cohort study.
Yoon JH; Kim HJ; Kwak DH; Park SS; Jeon YW; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS
J Hematol Oncol; 2017 Jan; 10(1):30. PubMed ID: 28114959
[TBL] [Abstract][Full Text] [Related]
40. Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalpha-positive leukemic stem cells.
Zheng X; Seshire A; Rüster B; Bug G; Beissert T; Puccetti E; Hoelzer D; Henschler R; Ruthardt M
Haematologica; 2007 Mar; 92(3):323-31. PubMed ID: 17339181
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
